Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Algernon Pharmaceuticals Inc
AGNPF
Primary Symbol:
C.AGN
Consumer Cyclical
Healthcare
Advertising Agencies
Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N...
-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (CSE:AGN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(49)
•••
bmreed
X
View Profile
View Bullboard History
Post by
bmreed
on Apr 22, 2024 1:55pm
Webinar Recap: $AGN CEO Chris Moreau and Radius Research
(49)
•••
bmreed
X
View Profile
View Bullboard History
Post by
bmreed
on Apr 10, 2024 2:07pm
Webinar $AGN CEO Chris Moreau Tue Apr 16 @ 4PM ET / 1PM PT
RESCHEDULED: Live Webinar - Algernon Pharmaceuticals $AGN w/ CEO Christopher Moreau Tuesday, April 16th at 4PM ET / 1PM PT Q&A with Radius Research Register Here - https://us02web
...more
New PEA Indicates an Ultra Low-Cost Uranium Project with Huge Exploration Upside
posted Apr 26, 2024 9:00am by
Blue Sky Uranium Corp
-
|
This PEA reaffirms that the deposit is a leading low-cost uranium-vanadium project. We believe that this resurgent uranium market has a strong long-term outlook and we are therefore preparing to complete a prefeasibility study as soon as possible ...read more
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on Mar 21, 2024 10:09am
Tuesday’s Trading
Out of the country so catching up . Tursday's trading brought the price by one cent and the usual kids in the sandbox were involved. Howevee, there was one interesting new player- Credential
...more
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on Mar 07, 2024 5:02pm
Today’s Trading
Same old same old. Desjardins and National flinging nickels around like manhole covers.
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on Feb 23, 2024 7:24pm
Today’s Trading
No Trading in the sandbox today -unless you count the Quebec kids, Laurentian and Desjardiin the
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on Feb 06, 2024 5:01pm
Today’s Trading
A busy day in the sandbox with over 100,000 shares traded. The Quebec kids were very active and the price dropped one cent today, like yesterday, to finish at 7 cents. Meanwhile at OTC, with no
...more
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on Feb 05, 2024 5:07pm
Today’s Trading
Relatively big spread bid and ask 08/095 for about four hours then three trades at $0.08 all from TDSecurities and all to the Quebec kids I wonder who owned the TD account.
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on Feb 01, 2024 4:29pm
Today’s Trading
Moderate trading, sans Quebec, and price rises to 9 cents. late in the day we had two mini trades - totalling $240, and involving the Quebec kids exclusively, brought the price down to 8 cents, for
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 31, 2024 7:00am
New Press Release - Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of intention to...
read article.
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on Jan 29, 2024 2:40pm
Today’s Trading
BC based AGN is down today. All trades so far have been between the Quebec kids, Desjardins and National Bank, exclusively.
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on Jan 18, 2024 4:37pm
Today’s Trading
Only three trades today -all involving, exclusively, Desjardins and National Bank. The Quebec kids are now in charge of the sandbox.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 11, 2024 7:00am
New Press Release - Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
VANCOUVER, British Columbia, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company is pleased to announce that it has received a notice of allowance...
read article.
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on Jan 09, 2024 6:41pm
Today’s Trading
Interesting! Seven (7) trades today. After closing at 0.095 yesterday and hours of inactivity today, Desjardins makes an $85 trade so the market price is 0.085. Next we have TD Securities buying 2000
...more
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on Jan 08, 2024 1:23pm
Today’s Trading
Only one trade today - knocking 11%%, $200,000 off a company whose research could bring relief from suffering to millions of people. the seller is Desjardins, whose web site states that it is "
...more
(18)
•••
nodaytrader
X
View Profile
View Bullboard History
Post by
nodaytrader
on Jan 03, 2024 11:00am
Today’s Tradink
An encouraging start to trading worth share price quickly rising to $0.105. However, we have al learned to expect price depressing mini trades to claw back the gains. Well, it has started with a
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Two New Contracts Awarded Covering Five Onshore Fields Producing 3,000 bbl/d of Oil
Fresh Insight into the Topaz HELIUM Project's Expected Size and Scale
Exploration company provides project portfolio update
Centurion Identifies High Quality Gold Target-Casa Berardi West Project; Acquires Additional Claims
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study